Testosterone Cypionate — How Does It Differ From Enanthate?

Understand

Overview

Testosterone cypionate (testosterone cyclopentylpropionate) is, alongside enanthate, one of the two most widely used injectable testosterone esters in testosterone replacement therapy (TRT) worldwide — with the caveat that cypionate is the dominant choice in the United States, while enanthate is more commonly found in Europe, including Poland. In terms of the molecule itself, the two esters are very close: they differ only in the structure of the fatty-acid chain attached to testosterone, and once in circulation, plasma esterases release identical, bioidentical hormone from both. A full comparison of the chemistry and pharmacokinetics of the two esters is covered in a dedicated entry on the differences between enanthate and cypionate — here we don't repeat that analysis, but focus on what's specific and practically relevant to cypionate itself: population modeling of its pharmacokinetics and the genuinely debated question of injection route.

One of the most detailed sources of data on how cypionate behaves in the body is the population pharmacokinetic/pharmacodynamic modeling conducted by Bi and colleagues (2018). In this study, 31 healthy men received weekly intramuscular cypionate injections for 14 weeks at doses of 100, 250, or 500mg per week — it must be emphasized that these were supraphysiological, research doses, considerably higher than typical doses used in standard replacement therapy, deliberately chosen to build a dose-response model rather than to mimic a typical TRT protocol. Based on this data, the authors built a one-compartment pharmacokinetic model in which cypionate clearance was 2.6 kL/day and the volume of distribution 14.4 kL. The estimated potency of total testosterone needed for LH suppression was estimated at 9.33 ng/mL — a value useful mainly for pharmacological modeling and designing future studies, not as a direct dosing guide for an individual patient.

A separate, practically significant question concerns cypionate's route of administration — intramuscular versus subcutaneous. A study by McFarland and colleagues (2017) included 11 patients on weekly subcutaneous cypionate injections, with blood samples drawn at 8 time points across the week between doses. Mean total testosterone was 627±206 ng/dL (range 205-1410), and free testosterone 146±51 pg/mL (range 38-348), remaining stable throughout the week between injections. It's worth stating clearly, though: the study cohort consisted of transgender men, not a typical population of hypogonadal men — the authors assume the results should extend to hypogonadal men, but the study itself doesn't directly confirm this in that population.

The most direct comparison of injection route comes from a retrospective study by Choi and colleagues (2022) in 234 hypogonadal men, comparing intramuscular cypionate (100mg weekly) with subcutaneous enanthate (100mg weekly) over 12 weeks of therapy. Both groups saw a significant rise in trough testosterone: from 313.6 to 536.4 ng/dL with intramuscular cypionate, and from 246.6 to 552.8 ng/dL with subcutaneous enanthate (both p<0.001), with no significant difference between the two modalities in final trough concentration (p=0.057). The subcutaneous route was independently associated with a lower rise in estradiol and lower hematocrit (both p<0.001), and neither modality significantly raised PSA (p=0.965). Here, however, an important caveat is essential and easy to overlook: this comparison changed two variables at once — both the ester (cypionate vs. enanthate) and the route (intramuscular vs. subcutaneous) — so it's evidence primarily about route of administration, not a clean, controlled comparison of the ester alone. This result shouldn't therefore be read as proof that "cypionate causes worse hematocrit or estradiol than enanthate" — ester and route were confounded together in this study.

Additional context comes from a study by Wilson and colleagues (2018), comparing the pharmacokinetics, safety, and patient acceptability of both injection routes. Dose-normalized area under the curve (AUC) was comparable between routes: 1.7±0.6 for subcutaneous versus 1.9±0.6 nmol·days/L/mg for intramuscular. The subcutaneous route was also associated with lower pre-injection anxiety reported by patients — though this is a finding about subjective patient experience and treatment acceptability, not a hormonal parameter.

Putting this data together, the practical picture is as follows: the cypionate molecule itself, regardless of route, releases testosterone at a rate comparable to other esters at similar dosing, and the decision about route of administration (intramuscular vs. subcutaneous) appears to have a larger effect on parameters like estradiol or hematocrit than the choice of ester itself. This is useful practical information, but not a basis for self-directed changes to route of administration — the decision of whether to give cypionate intramuscularly or subcutaneously, and how often, should be made by the physician managing therapy, based on the individual clinical picture, blood test results, and patient preference.